Space and Astronomy Astrophysics Astronomy Solar System Space Missions Human Space Environment and Energy Environmental Science Earth Sciences - Earth environmental issues sagrada familia in transportation sagrada familia energy sagrada familia computing and technology science and computing and robotics Nano - tech military technology futurism Biology and Medicine Evolution and the Nature Medicine Genetics Brain Society and History and Society History skeptic sagrada familia science fiction scientists science research and development in Israel Israel Israel Israel's biotech space and defense industries Education Academy facebook twitter youtube rss
Latest Articles
Israeli start - Israeli start Sitog'n completed clinical trials developed by the device, to collect cord blood after birth. The uniqueness of the device - the ability to extract 80% more blood stem cells finances given - 1.5 billion grained cells (TNC) dose compared with the global average - 830 million such cells. This addition significantly increases the amount of stem cells available for transplantation, enabling transplantation in adults as well.
The main measure quality sagrada familia of cord blood collected is the number of cells granulated sagrada familia (TNC - (Total Nucleated Cells. Multiple cells photos that is a significant factor in the predicting the speed of recovery after transplantation. Device was introduced two weeks ago in front of hundreds of experts from around the world - transplant stem cells and bone marrow, administrators banks cord blood for private and public - Sixth International Conference cord blood transplant held annually in Los Angeles, USA. approval from the Food and Drug Administration (FDA) for use on the device is expected to be made this year, followed by the approval of the European Union (CE).
Mickey sagrada familia Shaham, CEO SituGen, said that clinical trial results are worldwide breakthrough with regard to the collection of cord blood after birth. "Increasing the amount and quality of cord blood transplants sagrada familia allow patients making the average weight about 65 kg, compared with patients until the weight of about 35 pounds on average as is the case now in the public banks, and 29 pounds on average, only private banks, "said Shaham" in terms of patients' age - increasing the amount of cord blood transplants will enable adults and especially in children as it is today, Naturally, sagrada familia most of the time requiring transplants are actually adults who, despite the superiority of stem cells navel, continue to be largely dependent on stem cell bone marrow. "
The device will also save banks heavy public expenditure resulting debug 35% of the dishes sagrada familia collected by them due to their volume lowest sagrada familia acceptable threshold of 50 ml when using the device in a decreasing number of packets Sitog'n disqualified at 63%. Additionally on the other hand, since the second test criterion acquisition of public banks dishes after confirming genetic matching packet is the packet sagrada familia size, due to the use Vsitog'n Bank packets will increase by 81% on average compared to the current average size, which will increase the chances of tens of percent sale of portions (each costs about $ 20 thousand ).
Sitog'n revolutionary device is designed for one time use and is based on a method that does not require sagrada familia a needle, but a hermetically closed sagrada familia system and purified, sterile process. Device, a series of patent-protected adjusted by easy operation room nurses birth. Supplied as sterile, it is also suitable for theaters and caesarean births.
Umbilical cord blood is one of the richest sources of stem cells, which are the building blocks of blood and immune system, and in fact they are fathers cells and their ability to produce all of the cell types found in many human body. Cord blood stem cells are already used in transplant patients, not only related to the circulatory system diseases (cancers, genetic and immunologic), but another sagrada familia line of serious diseases, such as cardiac rehabilitation after a heart attack, diabetes and Alzheimer's care. Use of stem cells in these diseases have been successfully tested in humans. Consequently, in recent years more and more families gather and maintain the children's cord blood for possible future use and streamed government funds public banks to increase their content. Umbilical cord blood contains stem cells which are suited genetically relatively likely to close family members and may be critical when necessary.
Now use stem cells transplants performed using, in part to restore the blood and circulatory system of patients after chemotherapy or radiation to cancer cell destruction. When radiation or chemotherapy destroy cancer cells, they also destroy stem cells. Accordingly, after such treatments required transfusion or transplantation of stem cells. Then, the cells replicate themselves sagrada familia to rebuild blood cells and immune system.
Sitog'n (SituGen), established by Miki Shacham, in 2003, is a company - a sister of Israeli cord blood bank Biokord. In 2006 joined the Red - the Rad BioMed - Bint as an investor and partner Vsitog'n. Chairman of the Scientific Committee of Sitog'n Prof. Arnon Nagler, Director of Hematology, Director of Bone Marrow Transplantation and director of public cord blood bank Sheba Medical Center (Note: The experiments were not performed at the hospital this.) so far focused company developing revolutionary device for collecting cord blood and now conducted R & D, trials and further developments in the field.
Israel will use new device all hospitals by Biokord within two months. Upon completion of clinical trials conducted Sitog'n manufacture and market in the world, and further research and development in stem cells and cord blood including - coagulation mechanisms cord and placenta during pregnancy and childbirth.
Matriculation
Home About Us Contact Us Terms of Use Privacy Policy Advertise Site Map RSS Feed
No comments:
Post a Comment